The U.S. Department of Health and Human Services, through the Food and Drug Administration (FDA), intends to award a firm fixed price purchase order to Bruker BioSpin Corporation for an annual helium fill service agreement supporting an Avance 600 MHz nuclear magnetic resonance (NMR) spectrometer at the FDA's St. Louis laboratory. This procurement is essential for maintaining the operational integrity of the NMR spectrometer, which is critical for research and evaluation within the Center for Drug Evaluation and Research (CDER). As Bruker BioSpin is the original equipment manufacturer, it is the sole source capable of providing the necessary OEM compliant service, ensuring specialized support from trained engineers. Interested parties, particularly small businesses, may express their capabilities to the Contract Specialist, Erika Crawford, at erika.crawford@fda.hhs.gov by 10:00 AM EST on December 27, 2024, to potentially influence the government's decision on competition.